MediWound (NASDAQ:MDWD) Upgraded by StockNews.com to Sell Rating

MediWound (NASDAQ:MDWD) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Friday.

Other research analysts have also issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of MediWound in a research report on Thursday. Craig Hallum assumed coverage on shares of MediWound in a report on Friday, February 28th. They issued a “buy” rating and a $39.00 target price for the company.

MediWound Stock Performance

NASDAQ MDWD opened at $16.27 on Friday. MediWound has a one year low of $12.78 and a one year high of $24.00. The company has a market capitalization of $175.60 million, a price-to-earnings ratio of -5.61 and a beta of 0.82. The company’s 50-day simple moving average is $18.17 and its two-hundred day simple moving average is $17.59.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.23. The company had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period last year, the company posted ($0.19) earnings per share. Equities analysts expect that MediWound will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

Large investors have recently made changes to their positions in the business. R Squared Ltd acquired a new stake in shares of MediWound in the 4th quarter worth $32,000. Russell Investments Group Ltd. raised its stake in MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,162 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in MediWound in the third quarter worth about $89,000. Bank of America Corp DE grew its stake in shares of MediWound by 38.0% during the fourth quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after acquiring an additional 2,178 shares during the last quarter. Finally, Rhumbline Advisers grew its position in MediWound by 7.3% during the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares during the last quarter. 46.83% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.